

September 9, 2021



## **ZyVersa Therapeutics' CEO, Stephen C. Glover Invited Panel Member at Inflammasome Therapeutics Summit 2021**

**Annual Inflammasome Summit unites world renowned experts in inflammasome-targeted drug development and academia to share information and address knowledge gaps in this rapidly evolving field**

**ZyVersa is well positioned in the emerging inflammasome space with a highly differentiated inflammasome ASC inhibitor (IC 100), which has potential to treat a broad range of inflammatory diseases**

WESTON, Fla., Sept. 9, 2021 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa's Co-Founder, Chief Executive Officer, and Chairman, is an invited panel member at the Inflammasome Therapeutics Summit 2021. The virtual conference is being held November 16-18, 2021.



---

To learn more about ZyVersa and its inflammasome ASC inhibitor, IC 100, please request a one-on-one virtual meeting.

---

Mr. Glover and the other panel members, Paul Ashton, President & CEO of Inflammasome Therapeutics, and Anil K. Goyal, CEO & Chairperson of IMMvention Therapeutix, will address thought-provoking topics including:

- Key learnings from recent progress and failures
- Drivers of inflammasome therapeutics development
- Market opportunity and untapped clinical areas
- Bottlenecks in inflammasome therapeutics clinical success

The panel discussion will take place:

**Date: Wednesday, November 17th**

**Time: 9:00-9:30 am ET**

**Event Registration Link: [Inflammasome Therapeutics Summit 2021](#)**

To learn more about ZyVersa and its inflammasome ASC inhibitor, IC 100, please request a one-on-one virtual meeting.

### **About ZyVersa Therapeutics, Inc.**

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs. Our development pipeline includes a novel inflammasome inhibitor with potential to treat multiple inflammatory diseases, and phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of a rare kidney disease, focal segmental glomerulosclerosis (FSGS), with potential to treat other kidney diseases. For more information, please visit [www.zyversa.com](http://www.zyversa.com).

# ZyVersa

THERAPEUTICS<sup>SM</sup>

View original content to download multimedia <https://www.prnewswire.com/news-releases/zyversa-therapeutics-ceo-stephen-c-glover-invited-panel-member-at-inflammasome-therapeutics-summit-2021-301371844.html>

SOURCE ZyVersa Therapeutics, Inc.